Company news
Arecor Therapeutics Plc (LSE:AREC) news
Every Arecor Therapeutics Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
AT278 data published in peer-reviewed journal
August 13, 2026
Grant of options and PDMR dealing
May 21, 2026
Upcoming conference attendance
May 18, 2026
Posting of Annual Report and Notice of AGMm
April 28, 2026
Final Results
April 13, 2026
Notice of FY25 Results
March 30, 2026
Ligand Pharmaceuticals Milestone Payment
March 26, 2026
Arecor to present at Oppenheimer conference
March 9, 2026
2025 Business Update
February 9, 2026
Fireside Panel Discussion on Diabetes sector
January 6, 2026
Arecor and Sequel Med Tech to host fireside panel
December 9, 2025
Holding(s) in Company
November 17, 2025
Enhanced IP Coverage: AT278 & Oral Peptide Program
November 4, 2025
Directorate Changes
September 29, 2025
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fe...
September 25, 2025
Co-Development Agreement & Monetisation Deal
September 25, 2025
Interim results for the six months to 30 June 2025
September 25, 2025
Notice of Interim Results
September 24, 2025
Positive FDA Feedback on Phase 2 Study Design
September 4, 2025
Change of Auditor
August 8, 2025
Arecor Establishes New Scientific Advisory Board
July 14, 2025
Grant of Options and PDMR Dealing
June 4, 2025
Result of AGM
June 2, 2025
Non-Executive Director Board Change
June 2, 2025
Director/PDMR Dealing
May 21, 2025
Arecor Partnership with Skye Bioscience
May 19, 2025
Director Dealing
May 14, 2025
Arecor sells rights to non-Ogluo® products
May 8, 2025
Posting of 2024 Annual Report and Notice of AGM
May 6, 2025
Arecor to present on Investor Meet Company
April 24, 2025
Final results for 2024
April 22, 2025
Notice of Results
April 10, 2025
Collaboration with global pharmaceutical partner
March 26, 2025
Arecor partnership with biopharmaceutical company
March 12, 2025
Arecor Full Year 2024 Trading Update
February 3, 2025
Orderly Cessation of Tetris Pharma Operations
January 10, 2025
Change of Nominated Advisor and Joint Broker
January 9, 2025
Arecor Signs Exclusive Licensing Agreement
December 30, 2024
Arecor Appoints Interim Chief Financial Officer
November 18, 2024
Interim Results for six months ended 30 June 2024
September 26, 2024
Arecor presents positive AT278 data at EASD
September 11, 2024
Arecor announces AT278 presentation at EASD 2024
September 3, 2024
Result of General Meeting and Total Voting Rights
August 8, 2024
Posting of Circular and General Meeting
July 23, 2024
Result of WRAP Retail Offer
July 23, 2024
Result of Placing and Subscription
July 19, 2024
WRAP Retail Offer to raise up to £1 million
July 19, 2024
Proposed Placing and Subscription
July 19, 2024
Trading and Funding Update
June 10, 2024
Posting of 2023 Annual Report and Notice of AGM
May 31, 2024